Cellceutix

March 23, 2017March 23, 2017

Positive Interim Trial Results of Brilacidin for IBD Announced by Cellceutix

News

Cellceutix announced additional interim positive findings from its ongoing Phase 2a trial evaluating brilacidin (PMX-30063) as a treatment for two types of inflammatory bowel disease (IBD) – ulcerative proctitis and ulcerative proctosigmoiditis (UP/UPS). ... Read more

February 27, 2017

Cellceutix’s IBD Therapy Brilacidin Progresses to Highest Dose Group in Phase 2 Trial

News

Cellceutix says the ongoing Phase 2 clinical trial of its lead drug candidate Brilacidin has progressed to its third cohort (highest dose) to induce remission of mild-to-moderate ulcerative colitis, now that the study’s Safety Committee has ... Read more

December 9, 2016

Cellceutix Initiates Dose Escalation in Phase 2 Trial of Brilacidin for Ulcerative Proctitis

News

Cellceutix has initiated the dose escalation of brilacidin (PMX-30063) in the second cohort of patients enrolled in a Phase 2 clinical trial evaluating the drug candidate for the treatment of ulcerative ... Read more